Albireo to Participate in Jefferies London Healthcare Conference
BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in the Jefferies London Healthcare Conference in London, UK, from November 15-17, 2022.
- BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in the Jefferies London Healthcare Conference in London, UK, from November 15-17, 2022.
- Simon Harford, Chief Financial Officer of Albireo, will be presenting on November 15, 2022, at 10:20 AM GMT.
- A replay of the webcast will be available on-demand on the Albireo Investors page: ir.albireopharma.com .
- Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat pediatric and adult liver diseases.